Montijo-Barrios E, Cadena F, Ramírez-Mayans JA, Gutiérrez-Castrellón P

Language: Spanish
References: 17
Page: 335-343
PDF size: 75.43 Kb.

ABSTRACT

Introduction. Acute respiratory infections are the second leading cause of morbidity in children under 18 years. Several drugs have been used with variable efficacy and safety, trying to reduce the associated symptoms and improve quality of life. Objective. To evaluate the efficacy and safety of buphenine, aminophenazone and diphenylpyraline hydrochloride when compared with placebo for the control of symptoms associated with common cold in children 6-24 months of age. Material and methods. Randomized clinical trial, double blind, placebo controlled, in 100 children ‹ 24 months of any gender, with symptoms associated to common cold. They received the drug under study vs. placebo for seven days. Both groups received acetaminophen. The change on common cold related symptoms were evaluated. Statistic analysis was made with STATA 11.0 for Mac. Results. Fifty-three children were randomized to study drug and forty-seven to placebo. Age of children in each group was similar (12.2 ± 5.8 months vs. 12.7 ± 5.8 months, p NS). There were significant differences between groups in relation to rhinorrea and sneezing resolution, with better results in Flumil^® group and no adverse events observed. Conclusions. The results in this study indicates that Flumil^® is a safe and effective drug for control of symptoms present in the common cold in children aged 6-24 months.

REFERENCES

1. Simasek M, Blandino DA. Treatment of the common cold. Am Fam Phys 2007; 75: 515-20.

2. Kogan MD, Pappas G, Yu SM, Kotelchuck M. Over-the-counter medication use among US preschool-age children. JAMA 1994; 272: 1025-30.

3. Taverner D, Latte J, Draper M. Nasal decongestants for the common cold. Cochrane Database Syst Rev 2004; (3): CD001953.

4. Taverner D, Latte J. Nasal decongestants for the common cold. Cochrane Database Syst Rev 2007; (1): CD001953.

5. Coutts SM, Khandwala A, Weinryb I. Antiallergic activity of nylidrin hydrochloride (RHC 3432-A). A lack of correlation between inhibition of mediator release and levels of cyclic AMP. Int Arch Allergy Appl Immunol 1983; 70(4): 303-10.

6. Nachtigall HB. Efficacy and safety of diphenyl-piraline for the treatment of patients with allergic rhinitis, allergic conjunctivitis or bronchial asthma. J Allerg 1956; 75: 123-45.

7. Maxwell MJ, et al. Effectiveness of diphenyl piraline in cases of chronic allergic rhinitis. Lancet 1951: 828-31.

8. Masson R. On a new principle in the management of the common cold in pediatric practice. Deutsches Medizinisches J 1964; 21: 734-6.

9. Betlejewski St. Clinical efficacy of ARBDI in acute & allergic rhinitis. Der Landarzt 1964; 5: 210-11.

10. Schneidt W. The treatment of rhinopharingytys in infants and young children. Arztliche Praxis 1965; 2: 55-66.

11. Tammaro AE, Corvi G, Madeddu A, Brembilla E. Vascular aspects of the common cold and results of treatment with a new antirhinitic. Gazz Med Ital 1965; 124: 301-3.

12. Isensee G. Oral therapeutics in premature pediatric children with rhinitis. Kinderarztliche Praxis 1967; 35: 42-5.

13. Criscione S, Porro E. Infectious agent-induced rhinitis. In: Raeburn D, Giembycz MA (eds.). Rhinitis: Immunopathology and Pharmacotherapy Basel. Birkhauser Verlag; 1997, p. 147-60.

14. Pappas DE, Hendley O, Hayden FG, Winther B. Symptom Profile of Common Colds in School-Aged Children. Pediatr Infect Dis J 2008; 27: 8-11.

15. Ho FN, Mursch JD, Ong BS, Perttula B. Consumer satisfaction with OTC drugs: an analysis using the confirmation/disconfirmation model. Health Marketing Quarterly 1997; 15(1): 103-1.

16. Kim Sy, Chang Y-J, Cho HM, Hwang Y-W, Moon YS. Nonsteroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev 2009; (3): CD006362. DOI: 10.1002/14651858.CD006362.pub2

17. Shefrin AE, Goldman RD. Use of over-the-counter cough and cold medications in children. Can Fam Phys 2009; 55: 1081-3.